Eli Lilly Shares Rally into Top 28 Despite 30% Drop in Trading Volume

On September 26, 2025, Eli Lilly (LLY) recorded a trading volume of $2.58 billion, marking a 30.26% decline from the previous day’s volume. The stock closed with a 1.39% gain, securing a position within the top 28 most actively traded equities of the day. The move followed a strategic update highlighting its diabetes drug portfolio, with analysts noting renewed investor confidence in long-term revenue potential from emerging market expansion plans.

Recent developments centered on regulatory progress for LLY’s next-generation GLP-1 candidate, which cleared Phase III trials earlier this month. The pipeline update, coupled with a revised guidance for 2026 R&D expenditures, drew mixed reactions from institutional investors. While short-term volatility persisted due to macroeconomic uncertainty, the company’s commitment to maintaining a 10% dividend yield was cited as a stabilizing factor for long-term holders.

To run this back-test accurately, I need to pin down a few implementation details: 1) Market universe—specify exchange criteria for the “top-500-by-volume” list. 2) Signal formation & execution price—confirm whether rankings use daily close prices with entries at next-day opens. 3) Transaction costs—define assumptions for round-trip costs if applicable. 4) Benchmark—indicate if results should be compared to indices like the S&P 500. 5) Risk controls—clarify constraints beyond the 1-day holding period. Once confirmed, the back-test will generate signals from January 1, 2022, to the present.